<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:43:22Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:3291836" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:3291836</identifier><datestamp>2012-03-21</datestamp><setSpec>springeropen</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Breast Cancer Res Treat</journal-id>
      <journal-title-group>
        <journal-title>Breast Cancer Research and Treatment</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0167-6806</issn>
      <issn pub-type="epub">1573-7217</issn>
      <publisher>
        <publisher-name>Springer US</publisher-name>
        <publisher-loc>Boston</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC3291836</article-id>
      <article-id pub-id-type="pmcid">PMC3291836</article-id>
      <article-id pub-id-type="pmc-uid">3291836</article-id>
      <article-id pub-id-type="pmid">20714802</article-id>
      <article-id pub-id-type="pmid">20714802</article-id>
      <article-id pub-id-type="publisher-id">1085</article-id>
      <article-id pub-id-type="doi">10.1007/s10549-010-1085-7</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Preclinical Study</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Koch</surname>
            <given-names>Manuel</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hussein</surname>
            <given-names>Fadi</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Woeste</surname>
            <given-names>Andreas</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>GrÃ¼ndker</surname>
            <given-names>Carsten</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Frontzek</surname>
            <given-names>Karl</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Emons</surname>
            <given-names>GÃ¼nter</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Hawighorst</surname>
            <given-names>Thomas</given-names>
          </name>
          <address>
            <phone>+49-551-39-6575</phone>
            <fax>+49-551-39-14983</fax>
            <email>thomas.hawighorst@med.uni-goettingen.de</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Institute for Oral and Musculoskeletal Biology, Department of Dermatology, Center for Biochemistry, Center for Molecular Medicine Cologne, Medical Faculty, University of Cologne, 50931 Cologne, Germany </aff>
        <aff id="Aff2"><label>2</label>Department of Gynecology and Obstetrics, University Medical Center GÃ¶ttingen, Georg-August-University GÃ¶ttingen, 37075 GÃ¶ttingen, Germany </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>17</day>
        <month>8</month>
        <year>2010</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>17</day>
        <month>8</month>
        <year>2010</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>7</month>
        <year>2011</year>
      </pub-date>
      <volume>128</volume>
      <issue>2</issue>
      <fpage>337</fpage>
      <lpage>346</lpage>
      <history>
        <date date-type="received">
          <day>16</day>
          <month>5</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>20</day>
          <month>7</month>
          <year>2010</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Â© Springer Science+Business Media, LLC. 2010</copyright-statement>
      </permissions>
      <abstract id="Abs1">
        <p>Thus far the clinical benefits seen in breast cancer patients treated with drugs targeting the vascular endothelial growth factor (VEGF) pathway are only modest. Consequently, additional antiangiogenic approaches for treatment of breast cancer need to be investigated. Thrombospondin-2 (TSP-2) has been shown to inhibit tumor growth and angiogenesis with a greater potency than the related molecule TSP-1. The systemic effects of TSP-2 on tumor metastasis and the underlying molecular mechanisms of the antiangiogenic activity of TSP-2 have remained poorly understood. We generated a recombinant fusion protein consisting of the N-terminal region of TSP-2 and the IgG-Fc1 fragment (N-TSP2-Fc) and could demonstrate that the antiangiogenic activity of N-TSP2-Fc is dependent on the CD36 receptor. We found that N-TSP2-Fc inhibited VEGF-induced tube formation of human dermal microvascular endothelial cells (HDMEC) on matrigel in vitro and that concurrent incubation of anti-CD36 antibody with N-TSP2-Fc resulted in tube formation that was comparable to untreated control. N-TSP2-Fc potently induced apoptosis of HDMEC in vitro in a CD36-dependent manner. Moreover, we could demonstrate a CD36 receptor-mediated loss of mitochondrial membrane potential and activation of caspase-3 in HDMEC in vitro. Daily intraperitoneal injections of N-TSP2-Fc resulted in a significant inhibition of the growth of human MDA-MB-435 and MDA-MB-231 tumor cells grown in the mammary gland of immunodeficient nude mice and in reduced tumor vascularization. Finally, increased serum concentrations of N-TSP2-Fc significantly inhibited regional metastasis to lymph nodes and distant metastasis to lung as shown by quantitative real-time <italic>alu</italic> PCR. These results identify N-TSP2-Fc as a potent systemic inhibitor of tumor metastasis and provide strong evidence for an important role of the CD36 receptor in mediating the antiangiogenic activity of TSP-2.</p>
        <sec>
          <title>Electronic supplementary material</title>
          <p>The online version of this article (doi:10.1007/s10549-010-1085-7) contains supplementary material, which is available to authorized users.</p>
        </sec>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Breast cancer</kwd>
        <kwd>Thrombospondin-2</kwd>
        <kwd>CD36</kwd>
        <kwd>Metastasis</kwd>
        <kwd>Angiogenesis</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>Â© Springer Science+Business Media, LLC. 2011</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p>There is large amount of evidence that tumor growth is dependent on angiogenesis [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Clinically, proof of concept has begun with the recent regulatory approvals of three antiangiogenic therapies targeting the vascular endothelial growth factor (VEGF) pathway. Despite early benefits seen in breast cancer patients treated with anti-VEGF therapies [<xref ref-type="bibr" rid="CR29">29</xref>], enduring efficacy with regard to survival benefits is relatively modest [<xref ref-type="bibr" rid="CR23">23</xref>]. In addition, recent data provided strong evidence that tumors may escape or become resistant to the antiangiogenic effects of blocking the VEGF signaling pathway [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. Therefore, additional antiangiogenic approaches need to be evaluated. Two members of the thrombospondin (TSP) family [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR22">22</xref>], TSP-1 and TSP-2, are important naturally occurring angiogenesis inhibitors. Both proteins were shown to have potent antiangiogenic activity by inhibiting endothelial cell proliferation, migration, and tube formation in response to multiple angiogenic stimuli [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR50">50</xref>], and by inhibiting angiogenic responses in a number of in vivo models [<xref ref-type="bibr" rid="CR1">1</xref>]. The antiangiogenic activity of TSP-1 was localized to the properdin-like type I repeats, also called thrombospondin structural homology repeats (TSR), in the N-terminal domain of TSP-1 [<xref ref-type="bibr" rid="CR20">20</xref>]. In contrast to TSP-1, the molecular mechanism of the antiangiogenic activity of TSP-2 has not been as well studied. Since it has been reported that TSP-2 is more effective in inhibiting tumor growth and angiogenesis than TSP-1 [<xref ref-type="bibr" rid="CR25">25</xref>] [<xref ref-type="bibr" rid="CR28">28</xref>] [<xref ref-type="bibr" rid="CR45">45</xref>], we generated a recombinant fusion protein consisting of the N-terminal region of TSP-2 and an IgG-Fc1 fragment (N-TSP2-Fc). N-TSP2-Fc contained the procollagen homology domain as well as three type I repeats of TSP-2. Here, we report that recombinant N-TSP2-Fc induced apoptosis of endothelial cells by CD36 receptor-mediated loss of mitochondrial membrane potential and activation of caspase-3. In contrast to the majority of experimental antiangiogenic studies that only focused on the effects on primary tumor growth, with much less attention on metastasis, we provide strong evidence that N-TSP2-Fc significantly inhibited tumor growth of xenotransplanted MDA-MB-435 and MDA-MB-231 breast cancer cells and both lymph node as well as lung metastasis of MDA-MB-435 tumor cells grown as xenotransplants in the mammary gland of nude mice.</p>
    </sec>
    <sec id="Sec2" sec-type="materials|methods">
      <title>Materials and methods</title>
      <sec id="Sec3">
        <title>Cell lines and culture</title>
        <p>Human MDA-MB-435 and MDA-MB-231 breast cancer cells were obtained from ATCC and maintained in DMEM medium (Invitrogen) containing 10% FCS, 4.5Â mg/ml glucose, 2Â mM <sc>l</sc>-glutamine, 100 units/ml penicillin G, and 100Â Î¼g/ml streptomycin. Human 293-EBNA (Epstein-Barr virus nuclear antigen) cells (Invitrogen) were maintained in DMEM/F12 medium (Invitrogen) containing 10% FCS, 15Â mM HEPES, 1.0Â Î¼g/ml puromycin, 100 units/ml penicillin G, 100Â Î¼g/ml streptomycin, and 0.25Â Î¼g/ml fungizone, amphotericin B (Invitrogen). Human dermal microvascular endothelial cells (HDMEC) from Promocell (Heidelberg, Germany) were cultured in ECGM-MV medium (Promocell) containing fetal calf serum (0.05Â ml/ml), endothelial cell growth supplement (0.004Â ml/ml), recombinant human epidermal growth factor (10Â ng/ml), heparin (22.5Â Î¼g/ml), hydrocortisone (1Â Î¼g/ml), and phenol red (0.62Â ng/ml) supplemented with 50Â U/ml penicillin and 50Â Î¼g/ml streptomycin.</p>
      </sec>
      <sec id="Sec4">
        <title>Cell transfection</title>
        <p>The coding sequences of the N-terminal region of TSP-2 (aa 18-550 of human TSP-2) and the Fc region of human IgG1 <italic>(hinge and CHâ²â² and CH3 domains)</italic> were obtained by PCR and cloned into the the NheI and BamHI sites of a modified pCEP4 expression vector [<xref ref-type="bibr" rid="CR24">24</xref>] that contains a cytomegalovirus enhancer/promoter, the EBNA-1 gene, and a puromycin selection cassette. Human 293-EBNA cells were stably transfected with the expression vector using the Fugene transfection reagent (Roche).</p>
      </sec>
      <sec id="Sec5">
        <title>Purification of recombinant N-TSP2-Fc</title>
        <p>The secreted fusion protein was purified from serum-free culture medium by using affinity chromatography with Protein G Sepharose (GE Healthcare Europe). The fusion protein was eluted with 0.1Â M glycine (pH 2.7), and each fraction was neutralized with 1Â M TrisâHCl (pH 9.0). After dialysis the protein was stored at â80Â°C. The protein concentration was determined using the BCA protein assay kit (Pierce).</p>
      </sec>
      <sec id="Sec6">
        <title>Tube formation assay</title>
        <p>Twenty-four-well plates were coated with 300Â Î¼l Matrigel (BD Pharmingen) and incubated for 1Â h at 37Â°C. HDMEC (1Â ÃÂ 10<sup>5</sup> cells) in ECGM-MV containing VEGF (20Â ng/ml) were seeded into duplicate and observed at 12Â h. The formation of tube-like structures was analyzed using an Olympus IX51 microscope. Images were captured and computer-assisted analyses of tube length were performed using the Photoshop CS3 software (Adobe Systems).</p>
      </sec>
      <sec id="Sec7">
        <title>Apoptosis assay</title>
        <p>Primary HDMEC incubated in ECGM containing VEGF<sub>165</sub> (R&amp;D Systems) at a concentration of 20Â ng/ml were incubated with 40Â Î¼g/ml of N-TSP2-Fc with or without concurrent addition of 10Â Î¼g/ml of blocking CD36 antibody (Abcam) for 72Â h. Apoptosis was evaluated by using a procedure similar to that described by Nicoletti et al. [<xref ref-type="bibr" rid="CR32">32</xref>]. Briefly, a pellet containing 1Â ÃÂ 10<sup>6</sup> HDMEC was gently resuspended in 500Â ml of hypotonic fluorochrome solution containing 0.1% Triton X-100 (Sigma), 0.1% sodium citrate, and 50Â mg/ml propidium iodide (Sigma). After overnight incubation the cell suspensions were assayed by flow cytometry analysis of cellular DNA content on a FACSCalibur equipment (Becton-Dickinson Immunocytometry Systems) using CellQuest software (Becton-Dickinson Immunocytometry Systems).</p>
      </sec>
      <sec id="Sec8">
        <title>Mitochondrial membrane potential measurement</title>
        <p>Human dermal microvascular endothelial cells cultured in ECGM containing VEGF<sub>165</sub> (R&amp;D Systems) at a concentration of 20Â ng/ml were incubated with 40Â Î¼g/ml of N-TSP2-Fc with or without concurrent addition of 10Â Î¼g/ml of blocking CD36 antibody (Abcam) for 72Â h. The mitochondrial membrane potential was analyzed using the JC-1 mitochondrial membrane potential detection kit (Biotium).</p>
      </sec>
      <sec id="Sec9">
        <title>Western blot analysis of caspase-3 activity</title>
        <p>Human dermal microvascular endothelial cells were treated with N-TSP2-Fc (final concentration 40Â Î¼g/ml) with or without concurrent addition of 10Â Î¼g/ml of blocking CD36 antibody (Abcam) for 72Â h. Cell lysates from HDMEC were separated on SDS/PAGE under reducing conditions and transferred to nitrocellulose membranes (HybonD-ECL, GE Healthcare Europe, Munich, Germany) and then immunoblotted with a rabbit anti-human active caspase-3 polyclonal antibody (BD Pharmingen). The specifically bound antibody was detected using the enhanced chemiluminescence kit (Millipore). The bands were analyzed using the Kodak image system (Kodak).</p>
      </sec>
      <sec id="Sec10">
        <title>Tumorigenesis and metastasis assay</title>
        <p>2Â ÃÂ 10<sup>6</sup> MDA-MB-435 or 5Â ÃÂ 10<sup>6</sup> MDA-MB-231 breast cancer cells were injected bilaterally into the second mammary fat pads of athymic, female, 6-week-old NCR nu/nu mice. The tumor volumes were calculated using the following formula: VolumeÂ =Â 4/3Â ÃÂ ÏÂ ÃÂ (1/2Â ÃÂ smaller diameter)<sup>2</sup>Â ÃÂ 1/2Â ÃÂ larger diameter. After euthanizing the mice, tumors, axillary lymph nodes, and lungs were removed from each mouse. The tissue was embedded in OCT compound or was snap frozen in liquid nitrogen. All animal studies were done according to the German ethical guidelines and the German laws for protection of animals.</p>
      </sec>
      <sec id="Sec11">
        <title>Inhibition ELISA</title>
        <p>Mice were intraperitoneally injected with N-TSP2-Fc (100Â Î¼g/100Â Î¼l PBS). Serum samples were obtained at various times (0, 0.5, 1, 2, 6, 12, and 24Â h) after injection. The concentration of TSP-2 was determined using an inhibition ELISA. 96-well plates (MaxiSorbTM, Nunc) were coated overnight with N-TSP2-Fc at a concentration of 1Â Î¼g/ml. The remaining reactive sites were blocked with 1% BSA. A polyclonal goat antibody directed against the N-terminal region of human TSP-2 (R&amp;D) was previously mixed in 96-well plates either with standard solutions of N-TSP2-Fc (ranging from 2Â pg/ml to 20Â Î¼g/ml) or with mouse serum to be tested that was diluted 1:50 and 1:500 with PBS. This mixture was added to the N-TSP2-Fc-coated wells and incubated for 2Â h at RT. The samples were assayed using a chemiluminescent substrate (SuperSignal ELISA Pico substrate). Luminescence was measured at 425Â nm using a multi-detection microplate reader (BioTek Instruments GmbH). Data were analyzed using the SigmaPlot software (Systat Software), and the concentration of TSP-2 in each sample was calculated from the standard curve.</p>
      </sec>
      <sec id="Sec12">
        <title>Analysis of tumor angiogenesis</title>
        <p>Cryostat sections (5Â Î¼m) were stained with a rat anti-mouse CD31 monoclonal antibody (BD Pharmingen). Representative sections obtained from five tumors were analyzed using an Olympus IX51 microscope. Images were captured and morphometric analyses were performed using the IP LAB software (Scanalytics) as described [<xref ref-type="bibr" rid="CR45">45</xref>]. Three different fields in each section were examined at 10Ã magnification, and the number of vessels per mm<sup>2</sup>, the vessel size, and the relative area occupied by tumor blood vessels within the tumors were determined.</p>
      </sec>
      <sec id="Sec13">
        <title>Quantitative analysis of metastasis</title>
        <p>The DNEasy Blood and Tissue Kit (Qiagen) was used for isolation of genomic DNA. Primers (Eurogentec) specific for the human <italic>alu</italic> sequences (sense: 5â²-CATGGTGAAACCCCGTCTCTA-3â²; and antisense: 5â²-GCCTCAGCCTCCCGAGTAG-3â²) were used to amplify human <italic>alu</italic> repeats present in genomic DNA that was extracted from mouse tissue. The internal TaqMan probe for <italic>alu</italic> (5â²-[YY]-ATTAGCCGGGCGTGGTGGC-[BHQ-1]-3â²) was 5â²-labeled with the reporter fluorescent dye Yakima Yellow (YY) and carried the non-fluorescent quencher dye Black Hole Quencher-1 (BHQ-1). The 18S rRNA control kit (Eurogentec) was used as an internal reference and was labeled with the reporter dye 6-carboxy-fluorescein (FAM) at the 5â² end and the quencher dye 6-carboxy-tetramethyl-rhodamin (TAMRA) at the 3â² end. PCRs were carried out in 25Â Î¼l using 2ÃTaqMan Universal PCR Master Mix (Applied Biosystems), 0.9Â Î¼M each <italic>alu</italic> specific oligonucleotide primer, 250nM internal <italic>alu</italic> probe, 1.5Â Î¼l 18S rRNA primer mix, 0.5Â Î¼l internal 18S rRNA probe, and 1Â Î¼l genomic DNA. The final concentration for genomic DNA was 5Â ng/Î¼l for lymph node tissue and 50Â ng/Î¼l for lung tissue. PCR was carried out for 2Â min at 50Â°C and for 10Â min at 95Â°C followed by 40 cycles of 15Â s at 95Â°C and 1Â min at 60Â°C using the ABI PRISMâ¢ 7700 Sequence Detector (Applied Biosystems). Serial dilution steps (1:10) of genomic DNA obtained from human MDA-MB-435 cells in genomic DNA were obtained from either mouse lymph node or lung tissue served to construct the calibration curves. The cycle at which the <italic>alu</italic> PCR product becomes detectable above background signal (Ct<sub><italic>alu</italic></sub>) was determined for each dilution series. The <italic>alu</italic> signal was normalized against the relative quantity of 18S rRNA and expressed as âCtÂ =Â Ct<sub><italic>alu</italic></sub>Â âÂ Ct<sub>18SrRNA</sub>. A standard curve was generated for each measurement by using the real-time PCR assay and by plotting âCt as a function of the relative amount of human DNA in murine DNA (%). The <italic>R</italic><sup>2</sup> value (correlation coefficient) was &gt;0.96 for all measurements demonstrating an excellent relationship between the <italic>alu</italic> signal and the relative amount of human DNA with a detection limit of 0.001% human DNA in murine DNA.</p>
      </sec>
      <sec id="Sec14">
        <title>Statistical analysis</title>
        <p>The two-sided unpaired t-test was used to analyze the tumor and metastasis data and to analyze the differences in microvessel density, vessel size, and total vascular area. Tube formation, apoptosis, mitochondrial membrane potential, and caspase-3 activity were analyzed for significant differences by one-way ANOVA followed by StudentâNewmanâKeulsâ test for comparison of individual groups, after a Bartlett test had shown that variances were homogenous.</p>
      </sec>
    </sec>
    <sec id="Sec15">
      <title>Results</title>
      <sec id="Sec16">
        <title>N-TSP2-Fc inhibits tube formation of CD36 positive endothelial cells</title>
        <p>Puromycin-selected human 293-EBNA cell clones secreting high amounts of N-TSP2-Fc were used for large-scale expression. The molecular weight of the purified recombinant protein was determined as approximately 110Â kDa by SDS-PAGE followed by western blot (data not shown). N-terminal amino acid sequence analysis confirmed that the recombinant protein included amino acid 18â550 of human TSP-2 containing the heparin-binding-domain, the procollagen-like domain, and the three type 1 (properdin-like) repeats. The antiangiogenic efficacy was analyzed by investigating the effect of N-TSP2-Fc on VEGF-induced tube formation of HDMEC cultured on matrigel. After 12Â h, formation of networks with interconnection of tube-like structures was detected in HDMEC culture (Fig.Â <xref rid="Fig1" ref-type="fig">1</xref>a). In contrast, only sparse tube-like structures were detected when HDMEC were treated with N-TSP2-Fc (Fig.Â <xref rid="Fig1" ref-type="fig">1</xref>c) resulting in a significant reduction of the average tube length by more than 50% (Fig.Â <xref rid="Fig1" ref-type="fig">1</xref>e). After incubation of HDMEC with blocking CD36 antibody addition of N-TSP2-Fc resulted in tube formation that was comparable to untreated control (Fig.Â <xref rid="Fig1" ref-type="fig">1</xref>d, e) demonstrating that activation of the CD36 receptor was involved in the pronounced inhibition of network formation by N-TSP2-Fc. Treatment of HDMEC with IgG-Fc did not show any significant effect on VEGF-induced network formation providing evidence that the Fc fragment is not involved in the antiangiogenic activity of N-TSP2-Fc (Fig.Â <xref rid="Fig1" ref-type="fig">1</xref>b, e).<fig id="Fig1"><label>Fig.Â 1</label><caption><p>N-TSP2-Fc inhibits HDMEC tube formation on Matrigel in a CD36-dependent manner. HDMEC were seeded on Matrigel in the presence of VEGF. Cultures were treated with either PBS (<bold>a</bold>), or IgG-Fc (<bold>b</bold>), or N-TSP2-Fc (<bold>c</bold>). In <bold>d</bold> HDMEC were incubated with both N-TSP2-Fc and blocking CD36 antibody (CD36 ab). (BarÂ =Â 200Â Î¼m). Quantitative image analysis of tube length (<bold>e</bold>) revealed that treatment with N-TSP2-Fc significantly reduced the average tube length as compared to control-treated HDMEC. After preincubation of HDMEC with a blocking CD36 antibody (CD36 ab) the average tube length was comparable in N-TSP2-Fc- and control-treated HDMEC. Treatment with IgG-Fc did not have any significant effects on the average tube length. Data are expressed as mean Â±Â SEM (<italic>n</italic>Â =Â 3). ***Â <italic>P</italic>Â &lt;Â 0.001</p></caption><graphic xlink:href="10549_2010_1085_Fig1_HTML" id="MO1"/></fig></p>
      </sec>
      <sec id="Sec17">
        <title>N-TSP2-Fc induces activation of apoptosis in microvascular endothelial cells</title>
        <p>Flow cytometry of the sub-G<sub>1</sub> apoptotic population showed that treatment of HDMEC with N-TSP2-Fc for 72Â h in the presence of VEGF resulted in a significant increase of apoptotic endothelial cells by more than 45% as compared to control-treated cells (Fig.Â <xref rid="Fig2" ref-type="fig">2</xref>a). Parallel incubation with blocking CD36 antibody attenuated N-TSP2-Fc-induced apoptosis in HDMEC to close to the basal level indicating that CD36 is required for the apoptotic activity of N-TSP2-Fc (Fig.Â <xref rid="Fig2" ref-type="fig">2</xref>a).<fig id="Fig2"><label>Fig.Â 2</label><caption><p>N-TSP2-Fc induces apoptosis of HDMEC by CD36 receptor-mediated loss of mitochondrial membrane potential and activation of caspase-3. Percentage of apoptotic HDMEC (<bold>a</bold>) was measured by flow cytometry. Treatment with N-TSP2-Fc resulted in a significant increase of HDMEC apoptosis (<bold>a</bold>). Concurrent addition of a blocking CD36 antibody (CD36 ab) with N-TSP2-Fc inhibited this effect (<bold>a</bold>). The percentage of mitochondrial membrane potential (<bold>b</bold>) was decreased after treatment of HDMEC with N-TSP2-Fc. Simultaneous incubation of N-TSP2-Fc with anti-CD36 antibody (CD36 ab) did not induce loss of mitochondrial membrane potential when compared to control HDMEC (<bold>b</bold>). Active caspase-3 was analyzed in HDMEC by western blot analysis (<bold>c</bold>). Image analysis (<bold>d</bold>) of the bands revealed that caspase-3 activity was increased by incubation of HDMEC with N-TSP2-Fc. Caspase-3 activity of control-treated HDMEC or HDMEC incubated with N-TSP2-Fc and concurrent addition of anti-CD36 antibody (CD36 ab) was comparable (<bold>d</bold>). In all experiments <bold>a</bold>â<bold>d</bold>, HDMEC were incubated with PBS (control), or with 40Â Î¼g/ml of N-TSP2-Fc, or with 40Â Î¼g/ml of N-TSP2-Fc plus 10Â Î¼g/ml of blocking CD36 antibody. All experiments were performed in the presence of VEGF (20Â ng/ml). Results are expressed as meanÂ <underline>+</underline>Â SEM (<italic>n</italic>Â =Â 3). **Â <italic>P</italic>Â &lt;Â 0.01, ***Â <italic>P</italic>Â &lt;Â 0.001</p></caption><graphic xlink:href="10549_2010_1085_Fig2_HTML" id="MO2"/></fig></p>
      </sec>
      <sec id="Sec18">
        <title>N-TSP2-Fc causes activation of caspase-3 and of the mitochondrial-dependent intrinsic pathway of apoptosis</title>
        <p>Treatment of HDMEC with N-TSP2-Fc for 72Â h resulted in a significant loss of mitochondrial membrane potential and decreased the mitochondrial membrane potential to 66% of control (=100%; <italic>P</italic>Â &lt;Â 0.001). When HDMEC were treated with CD36 blocking antibody, addition of N-TSP2-Fc failed to induce loss of mitochondrial membrane potential (Fig.Â <xref rid="Fig2" ref-type="fig">2</xref>b). In addition, treatment of HDMEC with N-TSP2-Fc for 72Â h significantly induced activation of caspase-3 by more than 100% as compared to PBS control (Fig.Â <xref rid="Fig2" ref-type="fig">2</xref>c, d). The activation of caspase-3 by N-TSP2-Fc was almost completely abrogated by parallel incubation of HDMEC with blocking CD36 antibody (Fig.Â <xref rid="Fig2" ref-type="fig">2</xref>c, d).</p>
      </sec>
      <sec id="Sec19">
        <title>Systemic treatment with N-TSP2-Fc inhibits tumor growth and angiogenesis</title>
        <p>MDA-MB-435 tumor cells were subcutaneously injected into the second mammary gland of nude mice. Six days after tumor cell injection mice received either vehicle control (PBS), IgG-Fc (5Â mg/kg/day), or N-TSP2-Fc (5Â mg/kg/day). Control-treated mice formed tumors reaching a volume of ~600Â mm<sup>3</sup> within 21Â days (Fig.Â <xref rid="Fig5" ref-type="supplementary-material">1S</xref>). Following systemic treatment with N-TSP2-Fc for 15Â days, MDA-MB-435 tumors reached a volume of ~220Â mm<sup>3</sup>, representing a 63% inhibition of tumor growth (<italic>P</italic>Â &lt;Â 0.001; Fig.Â <xref rid="Fig5" ref-type="supplementary-material">1S</xref>). At this time point, treatment with IgG-Fc did not result in any major difference of tumor growth as compared to control mice (<italic>P</italic>Â =Â 0.39; Fig.Â <xref rid="Fig5" ref-type="supplementary-material">1S</xref>). We next investigated whether the prolongation of the growth period might change the inhibitory effect on tumor growth by N-TSP2-Fc (5Â mg/kg body weight) treatment. After a growth period of 36Â days the experiment had to be terminated due to tumor burden and first signs of tumor ulceration in the control group according to the institutional regulations on animal experiments. Systemic treatment was initiated 6Â days after tumor cell injection and continued daily for 30Â days. The inhibitory effect of N-TSP2-Fc became highly significant at day 22 of MDA-MB-435 tumor growth and was maintained until the end of the growth period resulting in a 61% inhibition of tumor growth at day 36, compared to control-treated tumors (<italic>P</italic>Â &lt;Â 0.001; FigÂ <xref rid="Fig3" ref-type="fig">3</xref>a). To analyze tumor-associated vascularization frozen sections of MDA-MB-435 tumors were stained for the endothelial junction molecule CD31 [<xref ref-type="bibr" rid="CR13">13</xref>]. Computer-assisted morphometric image analysis revealed that both the vessel density (Fig.Â <xref rid="Fig3" ref-type="fig">3</xref>b) and the average vessel size (Fig.Â <xref rid="Fig3" ref-type="fig">3</xref>c) was significantly decreased in N-TSP2-Fc-treated tumors, as compared with control tumors, resulting in a significant decrease in the relative area occupied by tumor vessels by 67% (<italic>P</italic>Â &lt;Â 0.001; Fig.Â <xref rid="Fig3" ref-type="fig">3</xref>d). To determine the serum concentration of both TSP-2 and N-TSP2-Fc we established an inhibition ELISA using an antibody directed against the N-terminal region of TSP-2. The serum concentration of TSP-2 in untreated tumor-bearing mice was 28.4Â Â±Â 3.6Â ng/ml (TableÂ <xref rid="Tab1" ref-type="table">1</xref>). Intraperitoneal administration of N-TSP2-Fc resulted in an increase of the serum concentration of TSP-2 and this effect lasted up to 24Â h. Since intraperitoneal injection of PBS did not result in any major differences in the serum concentration of TSP-2 (data not shown) the observed higher level of serum TSP-2 is due to an increase of the concentration of recombinant N-TSP2-Fc. As early as 30Â min after intraperitoneal injection we found a strong increase in the serum level of N-TSP2-Fc (TableÂ <xref rid="Tab1" ref-type="table">1</xref>) that reached a peak at 1Â h after intraperitoneal injection. Afterward the serum concentration of N-TSP2-Fc rapidly decreased at 12Â h after injection and reached a serum concentration that was close to the TSP-2 level of untreated tumor-bearing mice at 24Â h after intraperitoneal administration (TableÂ <xref rid="Tab1" ref-type="table">1</xref>). In addition, we examined the effect of recombinant N-TSP2-Fc on in vivo tumor growth of orthotopically injected MDA-MB-231 breast cancer cells (Fig.Â <xref rid="Fig6" ref-type="supplementary-material">2S</xref>). One week after tumor cell injection, mice were treated daily either with N-TSP2-Fc (5Â mg/kg body weight) or vehicle control. Four weeks after tumor cell injection systemic treatment with N-TSP2-Fc resulted in a significant inhibition of xenotransplanted MDA-MB-231 breast carcinomas as compared to control-treated tumors (<italic>P</italic>Â &lt;Â 0.05; Fig.Â <xref rid="Fig6" ref-type="supplementary-material">2S</xref>).<fig id="Fig3"><label>Fig.Â 3</label><caption><p>Systemic treatment with N-TSP2-Fc inhibits in vivo growth and angiogenesis of MDA-MB-435 tumors grown in the mammary gland. PBS (control) or 5Â mg per kg body weight of N-TSP2-Fc were daily injected intraperitoneally, beginning at day 6 after tumor cell implantation. MDA-MB-435 tumor growth was inhibited by treatment with N-TSP2-Fc as compared with PBS control treatment (<bold>a</bold>). Computer-assisted image analysis of CD31-stained cryostat tumor sections revealed a significant reduction of the number of blood vessels per mm<sup>2</sup> tumor area (<bold>b</bold>), of the average vessel size (<bold>c</bold>), and of the relative tumor area covered by blood vessels (<bold>d</bold>) in mice treated with N-TSP2-Fc. CD31-stained blood vessels were evaluated in three different Ã10 fields in sections obtained from five different tumors for each treatment group. Data are expressed as meanÂ <underline>+</underline>Â SEM. ***Â <italic>P</italic>Â &lt;Â 0.001</p></caption><graphic xlink:href="10549_2010_1085_Fig3_HTML" id="MO3"/></fig><table-wrap id="Tab1"><label>TableÂ 1</label><caption><p>Intraperitoneal injection of N-TSP2-Fc results in increased serum level of TSP-2</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Time (h) after injection (i.p.)</th><th align="left">Serum concentration of TSP-2</th></tr></thead><tbody><tr><td align="left">0</td><td align="left">0.0284Â Â±Â 0.0036Â Î¼g/ml</td></tr><tr><td align="left">0.5</td><td align="left">16.8Â Â±Â 1.8Â Î¼g/ml</td></tr><tr><td align="left">1.0</td><td align="left">19.7Â Â±Â 3.8Â Î¼g/ml</td></tr><tr><td align="left">6.0</td><td align="left">0.198Â Â±Â 0.053Â Î¼g/ml</td></tr><tr><td align="left">12.0</td><td align="left">0.179Â Â± 0.043Â Î¼g/ml</td></tr><tr><td align="left">24.0</td><td align="left">0.029Â Â±Â 0.0063Â Î¼g/ml</td></tr></tbody></table><table-wrap-foot><p>After intraperitoneal injection of 100Â Î¼g of N-TSP2-Fc diluted in 100Â Î¼l PBS, serum levels of TSP-2 were measured by an inhibition ELISA using an antibody directed against the N-terminal region of TSP2. Data revealed that serum concentration of TSP-2 rapidly increased (0.5Â h) and reached a peak at 1Â h after intraperitoneal injection. The serum concentration of TSP-2 was increased for 24Â h</p></table-wrap-foot></table-wrap></p>
      </sec>
      <sec id="Sec20">
        <title>Systemic treatment with N-TSP2-Fc decreases metastasis</title>
        <p>Results of <italic>alu</italic> PCR indicated the presence of human DNA as early as 2Â weeks after tumor cell injection in both lymph node and lung tissue of tumor-bearing mice treated with vehicle control (Fig.Â <xref rid="Fig4" ref-type="fig">4</xref>a, b). The relative amount of human DNA in murine DNA at this time point was 0.41% in lymph node tissue and 0.024% in lung tissue of tumor-bearing mice as compared to the background signal of 7.4Â ÃÂ 10<sup>â4</sup> and 4.2Â ÃÂ 10<sup>â3</sup>% in non-tumor-bearing mice, respectively (Fig.Â <xref rid="Fig4" ref-type="fig">4</xref>a, b). Treatment of tumor-bearing mice with N-TSP2-Fc resulted in a significant reduction of both lymph node and lung metastasis at 2Â weeks after tumor implantation (Fig.Â <xref rid="Fig4" ref-type="fig">4</xref>a, b). At 5Â weeks after tumor cell injection the relative amount of human tumor DNA was reduced by 80% in lymph node tissue and by 68% in lung tissue of N-TSP2-Fc-treated mice as compared to control mice (Fig.Â <xref rid="Fig4" ref-type="fig">4</xref>a, b).<fig id="Fig4"><label>Fig.Â 4</label><caption><p>N-TSP2-Fc inhibits lymph node and lung metastasis. Quantitative real-time PCR was used to analyze human <italic>alu</italic> repeats from MDA-MB-435 tumor cells present in genomic murine DNA that was extracted from lymph node (<bold>a</bold>) and lung tissue (<bold>b</bold>). Lymph node (<bold>a</bold>) and lung (<bold>b</bold>) metastasis were analyzed at two and 5Â weeks after tumor cell implantation in mice treated either with PBS (control; <italic>n</italic>Â =Â 10) or N-TSP2-Fc (NTF; <italic>n</italic>Â =Â 10). To measure the background signal in murine lymph node and lung tissue, quantitative real-time <italic>alu</italic> PCR was performed in non-tumor-bearing mice (mice w/o tumor). Data revealed an increase of the percentage of human DNA in murine DNA obtained from lymph node and lung tissue of tumor-bearing mice at two and 5Â weeks after tumor cell transplantation when compared to mice without tumors indicating the metastatic spread of MDA-MB-435 tumor cells to the lymph nodes and lung. Treatment with N-TSP2-Fc resulted in a significant reduction of the percentage of human DNA in murine DNA obtained from lymph node and lung tissue at two and 5Â weeks after transplantation of MDA-MB-435 tumor cells in the mammary gland of nude mice. Values represent meanÂ <underline>+</underline>Â SEM. *Â <italic>P</italic>Â &lt;Â 0.05, **Â <italic>P</italic>Â &lt;Â 0.01, ***Â <italic>P</italic>Â &lt;Â 0.001</p></caption><graphic xlink:href="10549_2010_1085_Fig4_HTML" id="MO4"/></fig></p>
      </sec>
    </sec>
    <sec id="Sec21">
      <title>Discussion</title>
      <p>TSP-2 is a potent endogenous inhibitor of tumor growth and angiogenesis [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. The antitumoral effect of TSP-2 is stronger than the effect of TSP-1 [<xref ref-type="bibr" rid="CR45">45</xref>]. However, the exact molecular mechanism of the antiangiogenic activity of TSP-2 has not been as well studied as that of TSP-1. TSP-2 shows only low sequence homology to TSP-1 in the procollagen region. Moreover, a recombinant fragment of human TSP-2 that only included the N-terminal globular domain and the procollagen homology domain failed to significantly inhibit tumor growth and angiogenesis [<xref ref-type="bibr" rid="CR34">34</xref>]. Therefore, the antiangiogenic activity of TSP-2 might map to the properdin-like type 1 repeats [<xref ref-type="bibr" rid="CR46">46</xref>], which have been implicated in the antiangiogenic activity of TSP-1 [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. The antiangiogenic effects within the properdin-like type 1 repeats of TSP-1 are mediated partly through interaction of the CSVTCG sequence with the CD36 receptor on endothelial cells [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR46">46</xref>].</p>
      <p>We produced a recombinant fusion protein, N-TSP2-Fc, that encompasses the N-terminal globular region with all three type 1 repeats containing two CSVTCG sequence motifs within the first and second type 1 repeats. N-TSP2-Fc exerted potent antiangiogenic activity in vitro. We found that N-TSP2-Fc significantly inhibited HDMEC tube formation and induced HDMEC apoptosis. N-TSP2-Fc also resulted in a significant increase of caspase-3 activity and a significant loss of mitochondrial membrane potential in cultured HDMEC. Moreover, blockade of the CD36 receptor almost completely abrogated the reported in vitro effects of N-TSP2-Fc, strongly suggesting that the antiangiogenic activity of N-TSP2-Fc is mediated by CD36-dependent induction of endothelial cell apoptosis and at least in part through activation of the intrinsic apoptotic pathway. This is in agreement with the previously reported binding of TSP-2 to CD36 and lack of inhibition of angiogenesis by TSP-2 in CD36 null mice [<xref ref-type="bibr" rid="CR43">43</xref>]. The exact molecular mechanisms through which TSP-2 and TSRs induce activation of caspase-3 and promote CD36-mediated apoptosis remain to be elucidated.</p>
      <p>We investigated the efficacy of systemic therapy with N-TSP2-Fc on both tumor growth and metastasis. To this end we made use of MDA-MB-435 tumor cells representing a well-established orthotopic model system for the study of breast cancer metastasis. MDA-MB-435 cells form primary tumors when injected into the mammary fat pad of nude mice, and spontaneously metastasize from these tumors to the lymph nodes and lungs [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. However, in a microarray expression study MDA-MB-435 cells have been reported to cluster with several melanoma cell lines [<xref ref-type="bibr" rid="CR39">39</xref>], and it has been speculated that that MDA-MB-435 cell is instead the M14 melanoma cell line, due to an early cross-contamination of cell cultures [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. MDA-MB-435 cells have been shown to express melanocytic proteins [<xref ref-type="bibr" rid="CR42">42</xref>] as well as epithelial markers such as cytokeratin 19 and secrete milk proteins and lipids [<xref ref-type="bibr" rid="CR42">42</xref>] suggesting that MDA-MB-435 breast cancer cells may have undergone a lineage infidelity during tumor progression [<xref ref-type="bibr" rid="CR42">42</xref>]. Indeed, lineage infidelity has been seen in breast carcinomas that express both epithelial and melanoma-associated proteins [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. Very recently, Chambers [<xref ref-type="bibr" rid="CR9">9</xref>] reported that although currently available stocks of the MDA-MB-435 and M14 cell lines were shown to be virtually identical at the karyotype level [<xref ref-type="bibr" rid="CR38">38</xref>], the conclusion that M14 and MDA-MB-435 cells are of M14 melanoma origin is inconsistent with the fact that the M14 cell line derived from a male patient with metastatic melanoma [<xref ref-type="bibr" rid="CR10">10</xref>] and the female karyotypes of both cell lines at present [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. Chambers [<xref ref-type="bibr" rid="CR9">9</xref>] suggested that the evidence from the literature rather is consistent with cell lines being of MDA-MB-435 breast cancer origin and that the MDA-MB-435 cell line represents a poorly differentiated aggressive breast tumor line with expression of both epithelial and melanocytic markers. In addition, in a recent study on distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines Hollestelle et al. [<xref ref-type="bibr" rid="CR19">19</xref>] revealed that the MDA-MB-435 cell line was basal-type. They identified subtype-specific gene mutation profiles revealing that basal-type breast cancers may have a genetic basis similar to melanomas [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Hollestelle et al. concluded conclusively that MDA-MB-435 is a breast cancer cell line [<xref ref-type="bibr" rid="CR18">18</xref>].</p>
      <p>We provide strong evidence that intraperitoneally injected N-TSP2-Fc sufficiently reached the blood circulation as shown by an inhibition ELISA and thereby systemically inhibited MDA-MB-435 tumor progression due to an inhibition of angiogenesis. We could also demonstrate that IgG-Fc did not have any major effects on MDA-MB-435 tumor growth in vivo. In addition, the inhibitory effect of recombinant N-TSP2-Fc on the growth of breast carcinomas could be confirmed by using of another, MDA-MB-231 [<xref ref-type="bibr" rid="CR7">7</xref>], breast cancer cell line. Systemic treatment with N-TSP2-Fc also resulted in a significant inhibition of xenotransplanted MDA-MB-231 breast cancer cells. Our findings are consistent with recently reported growth inhibition of xenotransplanted A431 squamous cell carcinomas by intraperitoneal application of a recombinant TSP-2 protein that include TSR sequences [<xref ref-type="bibr" rid="CR34">34</xref>]. We have combined the accuracy and sensitivity of real-time PCR [<xref ref-type="bibr" rid="CR30">30</xref>] with the human specificity of <italic>alu</italic> sequences [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR54">54</xref>] for direct quantitative evaluation of metastatic MDA-MB-435 breast cancer cells in lymph nodes and lungs. As early as 2Â weeks after tumor cell injection we could detect human tumor cell DNA in lymph node and lung tissue of MDA-M-435 breast tumor-bearing mice. The amount of human DNA in the lungs was much lower than that in the lymph nodes, indicating that lymph node metastasis is an earlier event than distant lung metastasis. This is consistent with the clinical course of most breast cancer diseases [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. We also found significantly less human tumor cell DNA in the lymph nodes and lungs of N-TSP2-Fc-treated mice as compared to control-treated mice. The inhibitory effect on metastasis was maintained over the entire period of in vivo tumor growth. Even at 5Â weeks after tumor cell inoculation, both lymph node and lung metastasis were significantly reduced in N-TSP2-Fc-treated mice.</p>
      <p>Controversial findings have been reported regarding the effects of TSP-1 on metastasis [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>] [<xref ref-type="bibr" rid="CR47">47</xref>] [<xref ref-type="bibr" rid="CR51">51</xref>]. Recent in vitro [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR5">5</xref>] and in vivo [<xref ref-type="bibr" rid="CR53">53</xref>] data suggest that prometastatic effects of endogenous TSP-1 may involve the activation of transforming growth factor-Î² (TGF-Î²) via the unique sequence KRFK found between the first and second type 1 repeats of TSP-1 [<xref ref-type="bibr" rid="CR41">41</xref>]. Noteworthy, TSP-2 lacks the KRFK sequence, and recent studies have not found any evidence for activation of latent TGF-Î² by TSP-2 [<xref ref-type="bibr" rid="CR26">26</xref>]. Whether the lack of TGF-Î² activation may explain the lack of any reported prometastatic effect of TSP-2 remains to be further evaluated. In support of this hypothesis are recent findings demonstrating that lymph node metastasis was only observed in TSP-2-null mice but not in wild-type mice in a multistep chemically induced skin carcinogenesis protocol [<xref ref-type="bibr" rid="CR17">17</xref>] whereas in a transgenic mouse model of breast cancer pulmonary metastasis was increased in TSP-1 null mice as compared to wild-type mice [<xref ref-type="bibr" rid="CR53">53</xref>]. Recently, preclinical studies reported that angiogenesis inhibitors targeting the VEGF signaling pathway reduced primary tumor growth but promoted tumor invasiveness and metastasis in vivo [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. Multi-targeting of parallel angiogenesis regulating pathways have been proposed to improve the benefits of antiangiogenic drug therapy [<xref ref-type="bibr" rid="CR6">6</xref>]. Our results demonstrate that N-TSP2-Fc treatment potently inhibits both tumor growth and metastasis in vivo mediated by CD36-dependent inhibition of tumor angiogenesis, and they indicate its potential use for antiangiogenic combination therapies to treat breast cancer.</p>
    </sec>
    <sec sec-type="supplementary-material" id="AppESM1">
      <title>Electronic supplementary material</title>
      <sec id="SecESM1">
        <p>
          <supplementary-material id="Fig5" content-type="local-data">
            <media xlink:href="10549_2010_1085_Fig5_ESM.jpg">
              <label>Fig. 1S</label>
              <caption>
                <p>Systemic application of IgG-Fc does not inhibit in vivo growth of MDA-MB-435 tumors. PBS (control), or 5Â mg per kg body weight of N-TSP2-Fc were daily injected intraperitoneally. Systemic treatment was initiated 6Â days after tumor cell injection. At 21Â days after tumor cell injection systemic application of IgG-Fc did not result in any major difference as compared with PBS control. In contrast, MDA-MB-435 tumor growth was significantly inhibited by treatment with N-TSP2-Fc as compared with PBS control or with IgG-Fc treatment. Data are expressed as meanÂ Â±Â SEM</p>
              </caption>
            </media>
          </supplementary-material>
          <supplementary-material id="Fig6" content-type="local-data">
            <media xlink:href="10549_2010_1085_Fig6_ESM.jpg">
              <label>Fig. 2S</label>
              <caption>
                <p>Systemic treatment with N-TSP2-Fc inhibits in vivo growth of MDA-MB-435 breast cancer. PBS (control), or 5Â mg per kg body weight of N-TSP2-Fc were daily injected intraperitoneally, beginning at day 10 after tumor cell implantation. 18Â days after initiation of systemic treatment tumor growth of MDA-MB-231 breast carcinomas was significantly diminished by treatment with N-TSP2-Fc as compared with PBS control treatment. Values represent meansÂ Â±Â SEM (<italic>n</italic>Â =Â 5). *<italic>P</italic>&lt;0.05</p>
              </caption>
            </media>
          </supplementary-material>
        </p>
      </sec>
    </sec>
  </body>
  <back>
    <ack>
      <p>We thank Renate Dietrich, Matthias LÃ¤sche, and Hiltrud Schulz for excellent technical assistance. This study was supported by Deutsche Forschungsgemeinschaft grants (HA 2898 4-1 and 4-2, MK SFB 832 A8).</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Adams</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Lawler</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>The thrombospondins</article-title>
          <source>Int J Biochem Cell Biol</source>
          <year>2004</year>
          <volume>36</volume>
          <fpage>961</fpage>
          <lpage>968</lpage>
          <pub-id pub-id-type="doi">10.1016/j.biocel.2004.01.004</pub-id>
          <pub-id pub-id-type="pmid">15094109</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Albo</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Berger</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>TN</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Rothman</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Tuszynski</surname>
              <given-names>GP</given-names>
            </name>
          </person-group>
          <article-title>Thrombospondin-1 and transforming growth factor-beta l promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin system</article-title>
          <source>Surgery</source>
          <year>1997</year>
          <volume>122</volume>
          <fpage>493</fpage>
          <lpage>499</lpage>
          <pub-id pub-id-type="doi">10.1016/S0039-6060(97)90043-X</pub-id>
          <pub-id pub-id-type="pmid">9288157</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Albo</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Rothman</surname>
              <given-names>VL</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Tuszynski</surname>
              <given-names>GP</given-names>
            </name>
          </person-group>
          <article-title>Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor</article-title>
          <source>Br J Cancer</source>
          <year>2000</year>
          <volume>83</volume>
          <fpage>298</fpage>
          <lpage>306</lpage>
          <pub-id pub-id-type="doi">10.1054/bjoc.2000.1268</pub-id>
          <pub-id pub-id-type="pmid">10917542</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alix-Panabieres</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Muller</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Pantel</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Current status in human breast cancer micrometastasis</article-title>
          <source>Curr Opin Oncol</source>
          <year>2007</year>
          <volume>19</volume>
          <fpage>558</fpage>
          <lpage>563</lpage>
          <pub-id pub-id-type="doi">10.1097/CCO.0b013e3282f0ad79</pub-id>
          <pub-id pub-id-type="pmid">17906452</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arnoletti</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Albo</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Granick</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Solomon</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Castiglioni</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rothman</surname>
              <given-names>VL</given-names>
            </name>
            <name>
              <surname>Tuszynski</surname>
              <given-names>GP</given-names>
            </name>
          </person-group>
          <article-title>Thrombospondin and transforming growth factor-beta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells</article-title>
          <source>Cancer</source>
          <year>1995</year>
          <volume>76</volume>
          <fpage>998</fpage>
          <lpage>1005</lpage>
          <pub-id pub-id-type="doi">10.1002/1097-0142(19950915)76:6&lt;998::AID-CNCR2820760613&gt;3.0.CO;2-0</pub-id>
          <pub-id pub-id-type="pmid">8625226</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bergers</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hanahan</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Modes of resistance to anti-angiogenic therapy</article-title>
          <source>Nat Rev Cancer</source>
          <year>2008</year>
          <volume>8</volume>
          <fpage>592</fpage>
          <lpage>603</lpage>
          <pub-id pub-id-type="doi">10.1038/nrc2442</pub-id>
          <pub-id pub-id-type="pmid">18650835</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cailleau</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Olive</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Reeves</surname>
              <given-names>WJ</given-names>
              <suffix>Jr</suffix>
            </name>
          </person-group>
          <article-title>Breast tumor cell lines from pleural effusions</article-title>
          <source>J Natl Cancer Inst</source>
          <year>1974</year>
          <volume>53</volume>
          <fpage>661</fpage>
          <lpage>674</lpage>
          <pub-id pub-id-type="pmid">4412247</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carmeliet</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Jain</surname>
              <given-names>RK</given-names>
            </name>
          </person-group>
          <article-title>Angiogenesis in cancer and other diseases</article-title>
          <source>Nature</source>
          <year>2000</year>
          <volume>407</volume>
          <fpage>249</fpage>
          <lpage>257</lpage>
          <pub-id pub-id-type="doi">10.1038/35025220</pub-id>
          <pub-id pub-id-type="pmid">11001068</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chambers</surname>
              <given-names>AF</given-names>
            </name>
          </person-group>
          <article-title>MDA-MB-435 and M14 cell lines: identical but not M14 melanoma?</article-title>
          <source>Cancer Res</source>
          <year>2009</year>
          <volume>69</volume>
          <fpage>5292</fpage>
          <lpage>5293</lpage>
          <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-1528</pub-id>
          <pub-id pub-id-type="pmid">19549886</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chee</surname>
              <given-names>DO</given-names>
            </name>
            <name>
              <surname>Boddie</surname>
              <given-names>AW</given-names>
            </name>
            <name>
              <surname>Roth</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Holmes</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Morton</surname>
              <given-names>DL</given-names>
            </name>
          </person-group>
          <article-title>Production of melanoma-associated antigen(s) by a defined malignant melanoma cell strain grown in chemically defined medium</article-title>
          <source>Cancer Res</source>
          <year>1976</year>
          <volume>36</volume>
          <fpage>1503</fpage>
          <lpage>1509</lpage>
          <pub-id pub-id-type="pmid">1260767</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dawson</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Pearce</surname>
              <given-names>SF</given-names>
            </name>
            <name>
              <surname>Zhong</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Silverstein</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Frazier</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Bouck</surname>
              <given-names>NP</given-names>
            </name>
          </person-group>
          <article-title>CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells</article-title>
          <source>J Cell Biol</source>
          <year>1997</year>
          <volume>138</volume>
          <fpage>707</fpage>
          <lpage>717</lpage>
          <pub-id pub-id-type="doi">10.1083/jcb.138.3.707</pub-id>
          <pub-id pub-id-type="pmid">9245797</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dawson</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Volpert</surname>
              <given-names>OV</given-names>
            </name>
            <name>
              <surname>Pearce</surname>
              <given-names>SF</given-names>
            </name>
            <name>
              <surname>Schneider</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Silverstein</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Henkin</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bouck</surname>
              <given-names>NP</given-names>
            </name>
          </person-group>
          <article-title>Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat</article-title>
          <source>Mol Pharmacol</source>
          <year>1999</year>
          <volume>55</volume>
          <fpage>332</fpage>
          <lpage>338</lpage>
          <pub-id pub-id-type="pmid">9927626</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dejana</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Corada</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lampugnani</surname>
              <given-names>MG</given-names>
            </name>
          </person-group>
          <article-title>Endothelial cell-to-cell junctions</article-title>
          <source>FASEB J</source>
          <year>1995</year>
          <volume>9</volume>
          <fpage>910</fpage>
          <lpage>918</lpage>
          <pub-id pub-id-type="pmid">7615160</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ebos</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Cruz-Munoz</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Bjarnason</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Christensen</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Kerbel</surname>
              <given-names>RS</given-names>
            </name>
          </person-group>
          <article-title>Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis</article-title>
          <source>Cancer Cell</source>
          <year>2009</year>
          <volume>15</volume>
          <fpage>232</fpage>
          <lpage>239</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ccr.2009.01.021</pub-id>
          <pub-id pub-id-type="pmid">19249681</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ferrara</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kerbel</surname>
              <given-names>RS</given-names>
            </name>
          </person-group>
          <article-title>Angiogenesis as a therapeutic target</article-title>
          <source>Nature</source>
          <year>2005</year>
          <volume>438</volume>
          <fpage>967</fpage>
          <lpage>974</lpage>
          <pub-id pub-id-type="doi">10.1038/nature04483</pub-id>
          <pub-id pub-id-type="pmid">16355214</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Folkman</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Tumor angiogenesis: therapeutic implications</article-title>
          <source>N Engl J Med</source>
          <year>1971</year>
          <volume>285</volume>
          <fpage>1182</fpage>
          <lpage>1186</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJM197108122850711</pub-id>
          <pub-id pub-id-type="pmid">4938153</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hawighorst</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Velasco</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Streit</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hong</surname>
              <given-names>YK</given-names>
            </name>
            <name>
              <surname>Kyriakides</surname>
              <given-names>TR</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>LF</given-names>
            </name>
            <name>
              <surname>Bornstein</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Detmar</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Thrombospondin-2 plays a protective role in multistep carcinogenesis: a novel host anti-tumor defense mechanism</article-title>
          <source>EMBO J</source>
          <year>2001</year>
          <volume>20</volume>
          <fpage>2631</fpage>
          <lpage>2640</lpage>
          <pub-id pub-id-type="doi">10.1093/emboj/20.11.2631</pub-id>
          <pub-id pub-id-type="pmid">11387198</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hollestelle</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Schutte</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Comment Re: MDA-MB-435 and M14 cell lines: identical but not M14 Melanoma?</article-title>
          <source>Cancer Res</source>
          <year>2009</year>
          <volume>69</volume>
          <fpage>7893</fpage>
          <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-2396</pub-id>
          <pub-id pub-id-type="pmid">19723654</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hollestelle</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nagel</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Smid</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lam</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Elstrodt</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Wasielewski</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>French</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Peeters</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Rozendaal</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Riaz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Koopman</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Ten Hagen</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Leeuw</surname>
              <given-names>BH</given-names>
            </name>
            <name>
              <surname>Zwarthoff</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Teunisse</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Spek</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Klijn</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Dinjens</surname>
              <given-names>WN</given-names>
            </name>
            <name>
              <surname>Ethier</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Clevers</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Jochemsen</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Bakker</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Foekens</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Martens</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Schutte</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines</article-title>
          <source>Breast Cancer Res Treat</source>
          <year>2010</year>
          <volume>121</volume>
          <fpage>53</fpage>
          <lpage>64</lpage>
          <pub-id pub-id-type="doi">10.1007/s10549-009-0460-8</pub-id>
          <pub-id pub-id-type="pmid">19593635</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Iruela-Arispe</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Lombardo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Krutzsch</surname>
              <given-names>HC</given-names>
            </name>
            <name>
              <surname>Lawler</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>DD</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats</article-title>
          <source>Circulation</source>
          <year>1999</year>
          <volume>100</volume>
          <fpage>1423</fpage>
          <lpage>1431</lpage>
          <pub-id pub-id-type="pmid">10500044</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jimenez</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Volpert</surname>
              <given-names>OV</given-names>
            </name>
            <name>
              <surname>Crawford</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Febbraio</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Silverstein</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Bouck</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1</article-title>
          <source>Nat Med</source>
          <year>2000</year>
          <volume>6</volume>
          <fpage>41</fpage>
          <lpage>48</lpage>
          <pub-id pub-id-type="doi">10.1038/71517</pub-id>
          <pub-id pub-id-type="pmid">10613822</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kazerounian</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Yee</surname>
              <given-names>KO</given-names>
            </name>
            <name>
              <surname>Lawler</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Thrombospondins in cancer</article-title>
          <source>Cell Mol Life Sci</source>
          <year>2008</year>
          <volume>65</volume>
          <fpage>700</fpage>
          <lpage>712</lpage>
          <pub-id pub-id-type="doi">10.1007/s00018-007-7486-z</pub-id>
          <pub-id pub-id-type="pmid">18193162</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kerbel</surname>
              <given-names>RS</given-names>
            </name>
          </person-group>
          <article-title>Tumor angiogenesis</article-title>
          <source>N Engl J Med</source>
          <year>2008</year>
          <volume>358</volume>
          <fpage>2039</fpage>
          <lpage>2049</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMra0706596</pub-id>
          <pub-id pub-id-type="pmid">18463380</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koch</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Murrell</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Hunter</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Olson</surname>
              <given-names>PF</given-names>
            </name>
            <name>
              <surname>Jin</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Keene</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Brunken</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Burgeson</surname>
              <given-names>RE</given-names>
            </name>
          </person-group>
          <article-title>A novel member of the netrin family, beta-netrin, shares homology with the beta chain of laminin: identification, expression, and functional characterization</article-title>
          <source>J Cell Biol</source>
          <year>2000</year>
          <volume>151</volume>
          <fpage>221</fpage>
          <lpage>234</lpage>
          <pub-id pub-id-type="doi">10.1083/jcb.151.2.221</pub-id>
          <pub-id pub-id-type="pmid">11038171</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kyriakides</surname>
              <given-names>TR</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>YH</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>LT</given-names>
            </name>
            <name>
              <surname>Bain</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Danielson</surname>
              <given-names>KG</given-names>
            </name>
            <name>
              <surname>Iozzo</surname>
              <given-names>RV</given-names>
            </name>
            <name>
              <surname>LaMarca</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>McKinney</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Ginns</surname>
              <given-names>EI</given-names>
            </name>
            <name>
              <surname>Bornstein</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Mice that lack thrombospondin 2 display connective tissue abnormalities that are associated with disordered collagen fibrillogenesis, an increased vascular density, and a bleeding diathesis</article-title>
          <source>J Cell Biol</source>
          <year>1998</year>
          <volume>140</volume>
          <fpage>419</fpage>
          <lpage>430</lpage>
          <pub-id pub-id-type="doi">10.1083/jcb.140.2.419</pub-id>
          <pub-id pub-id-type="pmid">9442117</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kyriakides</surname>
              <given-names>TR</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>YH</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Huynh</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bornstein</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Altered extracellular matrix remodeling and angiogenesis in sponge granulomas of thrombospondin 2-null mice</article-title>
          <source>Am J Pathol</source>
          <year>2001</year>
          <volume>159</volume>
          <fpage>1255</fpage>
          <lpage>1262</lpage>
          <pub-id pub-id-type="doi">10.1016/S0002-9440(10)62512-6</pub-id>
          <pub-id pub-id-type="pmid">11583953</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lawler</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>The functions of thrombospondin-1 and-2</article-title>
          <source>Curr Opin Cell Biol</source>
          <year>2000</year>
          <volume>12</volume>
          <fpage>634</fpage>
          <lpage>640</lpage>
          <pub-id pub-id-type="doi">10.1016/S0955-0674(00)00143-5</pub-id>
          <pub-id pub-id-type="pmid">10978901</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lawler</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sunday</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Thibert</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Duquette</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>George</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Rayburn</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hynes</surname>
              <given-names>RO</given-names>
            </name>
          </person-group>
          <article-title>Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia</article-title>
          <source>J Clin Invest</source>
          <year>1998</year>
          <volume>101</volume>
          <fpage>982</fpage>
          <lpage>992</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI1684</pub-id>
          <pub-id pub-id-type="pmid">9486968</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Miller</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gralow</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Dickler</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cobleigh</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Perez</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Shenkier</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Cella</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Davidson</surname>
              <given-names>NE</given-names>
            </name>
          </person-group>
          <article-title>Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer</article-title>
          <source>N Engl J Med</source>
          <year>2007</year>
          <volume>357</volume>
          <fpage>2666</fpage>
          <lpage>2676</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa072113</pub-id>
          <pub-id pub-id-type="pmid">18160686</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mocellin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rossi</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Pilati</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Nitti</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Marincola</surname>
              <given-names>FM</given-names>
            </name>
          </person-group>
          <article-title>Quantitative real-time PCR: a powerful ally in cancer research</article-title>
          <source>Trends Mol Med</source>
          <year>2003</year>
          <volume>9</volume>
          <fpage>189</fpage>
          <lpage>195</lpage>
          <pub-id pub-id-type="doi">10.1016/S1471-4914(03)00047-9</pub-id>
          <pub-id pub-id-type="pmid">12763523</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nakagawa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Martinez</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Goto</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Koyanagi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kitago</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Shingai</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Elashoff</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Ye</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Singer</surname>
              <given-names>FR</given-names>
            </name>
            <name>
              <surname>Giuliano</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Hoon</surname>
              <given-names>DS</given-names>
            </name>
          </person-group>
          <article-title>Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes</article-title>
          <source>Clin Cancer Res</source>
          <year>2007</year>
          <volume>13</volume>
          <fpage>4105</fpage>
          <lpage>4110</lpage>
          <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-0419</pub-id>
          <pub-id pub-id-type="pmid">17634536</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nicoletti</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Migliorati</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Pagliacci</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Grignani</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Riccardi</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry</article-title>
          <source>J Immunol Methods</source>
          <year>1991</year>
          <volume>139</volume>
          <fpage>271</fpage>
          <lpage>279</lpage>
          <pub-id pub-id-type="doi">10.1016/0022-1759(91)90198-O</pub-id>
          <pub-id pub-id-type="pmid">1710634</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nobukawa</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Fujii</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hirai</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kumasaka</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Shimizu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Suda</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Futagawa</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Breast carcinoma diverging to aberrant melanocytic differentiation: a case report with histopathologic and loss of heterozygosity analyses</article-title>
          <source>Am J Surg Pathol</source>
          <year>1999</year>
          <volume>23</volume>
          <fpage>1280</fpage>
          <lpage>1287</lpage>
          <pub-id pub-id-type="doi">10.1097/00000478-199910000-00015</pub-id>
          <pub-id pub-id-type="pmid">10524531</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Noh</surname>
              <given-names>YH</given-names>
            </name>
            <name>
              <surname>Matsuda</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hong</surname>
              <given-names>YK</given-names>
            </name>
            <name>
              <surname>Kunstfeld</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Riccardi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Koch</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Oura</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Dadras</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Streit</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Detmar</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>An N-terminal 80Â kDa recombinant fragment of human thrombospondin-2 inhibits vascular endothelial growth factor induced endothelial cell migration in vitro and tumor growth and angiogenesis in vivo</article-title>
          <source>J Invest Dermatol</source>
          <year>2003</year>
          <volume>121</volume>
          <fpage>1536</fpage>
          <lpage>1543</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1523-1747.2003.12643.x</pub-id>
          <pub-id pub-id-type="pmid">14675207</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Padmore</surname>
              <given-names>RF</given-names>
            </name>
            <name>
              <surname>Lara</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Ackerman</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Gales</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sigurdson</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Ehya</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Cooper</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Patchefsky</surname>
              <given-names>AS</given-names>
            </name>
          </person-group>
          <article-title>Primary combined malignant melanoma and ductal carcinoma of the breast A report of two cases</article-title>
          <source>Cancer</source>
          <year>1996</year>
          <volume>78</volume>
          <fpage>2515</fpage>
          <lpage>2525</lpage>
          <pub-id pub-id-type="doi">10.1002/(SICI)1097-0142(19961215)78:12&lt;2515::AID-CNCR11&gt;3.0.CO;2-Z</pub-id>
          <pub-id pub-id-type="pmid">8952560</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Paez-Ribes</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Allen</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Hudock</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Takeda</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Okuyama</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Vinals</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Inoue</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bergers</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hanahan</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Casanovas</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis</article-title>
          <source>Cancer Cell</source>
          <year>2009</year>
          <volume>15</volume>
          <fpage>220</fpage>
          <lpage>231</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ccr.2009.01.027</pub-id>
          <pub-id pub-id-type="pmid">19249680</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Price</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Polyzos</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Daniels</surname>
              <given-names>LM</given-names>
            </name>
          </person-group>
          <article-title>Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice</article-title>
          <source>Cancer Res</source>
          <year>1990</year>
          <volume>50</volume>
          <fpage>717</fpage>
          <lpage>721</lpage>
          <pub-id pub-id-type="pmid">2297709</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rae</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Creighton</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Meck</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Haddad</surname>
              <given-names>BR</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>MD</given-names>
            </name>
          </person-group>
          <article-title>MDA-MB-435 cells are derived from M14 melanoma cellsâa loss for breast cancer, but a boon for melanoma research</article-title>
          <source>Breast Cancer Res Treat</source>
          <year>2007</year>
          <volume>104</volume>
          <fpage>13</fpage>
          <lpage>19</lpage>
          <pub-id pub-id-type="doi">10.1007/s10549-006-9392-8</pub-id>
          <pub-id pub-id-type="pmid">17004106</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ross</surname>
              <given-names>DT</given-names>
            </name>
            <name>
              <surname>Scherf</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Eisen</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Perou</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Rees</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Spellman</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Iyer</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Jeffrey</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Rijn</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Waltham</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pergamenschikov</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Lashkari</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Shalon</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Myers</surname>
              <given-names>TG</given-names>
            </name>
            <name>
              <surname>Weinstein</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Botstein</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>PO</given-names>
            </name>
          </person-group>
          <article-title>Systematic variation in gene expression patterns in human cancer cell lines</article-title>
          <source>Nat Genet</source>
          <year>2000</year>
          <volume>24</volume>
          <fpage>227</fpage>
          <lpage>235</lpage>
          <pub-id pub-id-type="doi">10.1038/73432</pub-id>
          <pub-id pub-id-type="pmid">10700174</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schneider</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Osl</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Friess</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Stockinger</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Scheuer</surname>
              <given-names>WV</given-names>
            </name>
          </person-group>
          <article-title>Quantification of human Alu sequences by real-time PCRâan improved method to measure therapeutic efficacy of anti-metastatic drugs in human xenotransplants</article-title>
          <source>Clin Exp Metastasis</source>
          <year>2002</year>
          <volume>19</volume>
          <fpage>571</fpage>
          <lpage>582</lpage>
          <pub-id pub-id-type="doi">10.1023/A:1020992411420</pub-id>
          <pub-id pub-id-type="pmid">12498386</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schultz-Cherry</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Mosher</surname>
              <given-names>DF</given-names>
            </name>
            <name>
              <surname>Misenheimer</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Krutzsch</surname>
              <given-names>HC</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Murphy-Ullrich</surname>
              <given-names>JE</given-names>
            </name>
          </person-group>
          <article-title>Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1</article-title>
          <source>J Biol Chem</source>
          <year>1995</year>
          <volume>270</volume>
          <fpage>7304</fpage>
          <lpage>7310</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.270.13.7304</pub-id>
          <pub-id pub-id-type="pmid">7706271</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sellappan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Grijalva</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Eli</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Mills</surname>
              <given-names>GB</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line</article-title>
          <source>Cancer Res</source>
          <year>2004</year>
          <volume>64</volume>
          <fpage>3479</fpage>
          <lpage>3485</lpage>
          <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-3299-2</pub-id>
          <pub-id pub-id-type="pmid">15150101</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Simantov</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Febbraio</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Silverstein</surname>
              <given-names>RL</given-names>
            </name>
          </person-group>
          <article-title>The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein</article-title>
          <source>Matrix Biol</source>
          <year>2005</year>
          <volume>24</volume>
          <fpage>27</fpage>
          <lpage>34</lpage>
          <pub-id pub-id-type="pmid">15748999</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Skobe</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hawighorst</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Jackson</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Prevo</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Janes</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Velasco</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Riccardi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Alitalo</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Claffey</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Detmar</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis</article-title>
          <source>Nat Med</source>
          <year>2001</year>
          <volume>7</volume>
          <fpage>192</fpage>
          <lpage>198</lpage>
          <pub-id pub-id-type="doi">10.1038/84643</pub-id>
          <pub-id pub-id-type="pmid">11175850</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Streit</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Riccardi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Velasco</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>LF</given-names>
            </name>
            <name>
              <surname>Hawighorst</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Bornstein</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Detmar</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>1999</year>
          <volume>96</volume>
          <fpage>14888</fpage>
          <lpage>14893</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.96.26.14888</pub-id>
          <pub-id pub-id-type="pmid">10611308</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tolsma</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Volpert</surname>
              <given-names>OV</given-names>
            </name>
            <name>
              <surname>Good</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Frazier</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Polverini</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Bouck</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity</article-title>
          <source>J Cell Biol</source>
          <year>1993</year>
          <volume>122</volume>
          <fpage>497</fpage>
          <lpage>511</lpage>
          <pub-id pub-id-type="doi">10.1083/jcb.122.2.497</pub-id>
          <pub-id pub-id-type="pmid">7686555</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Urquidi</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Sloan</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kawai</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Agarwal</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Woodman</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Tarin</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Goodison</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Contrasting expression of thrombospondin-1 and osteopontin correlates with absence or presence of metastatic phenotype in an isogenic model of spontaneous human breast cancer metastasis</article-title>
          <source>Clin Cancer Res</source>
          <year>2002</year>
          <volume>8</volume>
          <fpage>61</fpage>
          <lpage>74</lpage>
          <pub-id pub-id-type="pmid">11801541</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <mixed-citation publication-type="other">van der Horst EH, Leupold JH, Schubbert R, Ullrich A, Allgayer H (2004) TaqMan-based quantification of invasive cells in the chick embryo metastasis assay. Biotechniques 37:940â942, 944, 946</mixed-citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vogel</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>NH</given-names>
            </name>
            <name>
              <surname>Krutzsch</surname>
              <given-names>HC</given-names>
            </name>
            <name>
              <surname>Blake</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Hartman</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Mendelovitz</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Panet</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>DD</given-names>
            </name>
          </person-group>
          <article-title>Modulation of endothelial cell proliferation, adhesion, and motility by recombinant heparin-binding domain and synthetic peptides from the type I repeats of thrombospondin</article-title>
          <source>J Cell Biochem</source>
          <year>1993</year>
          <volume>53</volume>
          <fpage>74</fpage>
          <lpage>84</lpage>
          <pub-id pub-id-type="doi">10.1002/jcb.240530109</pub-id>
          <pub-id pub-id-type="pmid">8227183</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Volpert</surname>
              <given-names>OV</given-names>
            </name>
            <name>
              <surname>Tolsma</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Pellerin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Feige</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Mosher</surname>
              <given-names>DF</given-names>
            </name>
            <name>
              <surname>Bouck</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of angiogenesis by thrombospondin-2</article-title>
          <source>Biochem Biophys Res Commun</source>
          <year>1995</year>
          <volume>217</volume>
          <fpage>326</fpage>
          <lpage>332</lpage>
          <pub-id pub-id-type="doi">10.1006/bbrc.1995.2780</pub-id>
          <pub-id pub-id-type="pmid">8526929</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weinstat-Saslow</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Zabrenetzky</surname>
              <given-names>VS</given-names>
            </name>
            <name>
              <surname>VanHoutte</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Frazier</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Steeg</surname>
              <given-names>PS</given-names>
            </name>
          </person-group>
          <article-title>Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis</article-title>
          <source>Cancer Res</source>
          <year>1994</year>
          <volume>54</volume>
          <fpage>6504</fpage>
          <lpage>6511</lpage>
          <pub-id pub-id-type="pmid">7527299</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Welch</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
          <article-title>Technical considerations for studying cancer metastasis in vivo</article-title>
          <source>Clin Exp Metastasis</source>
          <year>1997</year>
          <volume>15</volume>
          <fpage>272</fpage>
          <lpage>306</lpage>
          <pub-id pub-id-type="doi">10.1023/A:1018477516367</pub-id>
          <pub-id pub-id-type="pmid">9174129</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yee</surname>
              <given-names>KO</given-names>
            </name>
            <name>
              <surname>Connolly</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Duquette</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kazerounian</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Washington</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lawler</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>The effect of thrombospondin-1 on breast cancer metastasis</article-title>
          <source>Breast Cancer Res Treat</source>
          <year>2009</year>
          <volume>114</volume>
          <fpage>85</fpage>
          <lpage>96</lpage>
          <pub-id pub-id-type="doi">10.1007/s10549-008-9992-6</pub-id>
          <pub-id pub-id-type="pmid">18409060</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zijlstra</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mellor</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Panzarella</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Aimes</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Hooper</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Marchenko</surname>
              <given-names>ND</given-names>
            </name>
            <name>
              <surname>Quigley</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>A quantitative analysis of rate-limiting steps in the metastatic cascade using human-specific real-time polymerase chain reaction</article-title>
          <source>Cancer Res</source>
          <year>2002</year>
          <volume>62</volume>
          <fpage>7083</fpage>
          <lpage>7092</lpage>
          <pub-id pub-id-type="pmid">12460930</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
    <fn-group>
      <fn>
        <p>Manuel Koch and Fadi Hussein contributed equally to this study.</p>
      </fn>
    </fn-group>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>